CA2563381C - Utilisation de sdg purifie comme antioxydant - Google Patents

Utilisation de sdg purifie comme antioxydant Download PDF

Info

Publication number: CA2563381C
Authority: CA; Canada
Prior art keywords: sdg; cholesterol; rats; group; control
Prior art date: 1996-04-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002563381A

Other languages

English (en)

Other versions

CA2563381A1 (fr

Inventor

Kailash Prasad

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Saskatchewan

Original Assignee

University of Saskatchewan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-04

Filing date

1997-04-03

Publication date

2008-01-22

1997-04-03 Application filed by University of Saskatchewan filed Critical University of Saskatchewan

1997-04-03 Priority claimed from CA002201652A external-priority patent/CA2201652C/fr

1997-10-04 Publication of CA2563381A1 publication Critical patent/CA2563381A1/fr

2008-01-22 Application granted granted Critical

2008-01-22 Publication of CA2563381C publication Critical patent/CA2563381C/fr

2017-04-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000003078 antioxidant effect Effects 0.000 title description 20
239000003963 antioxidant agent Substances 0.000 title description 18
SBVBJPHMDABKJV-PGCJWIIOSA-N secoisolariciresinol diglucoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-PGCJWIIOSA-N 0.000 claims abstract description 112
SBVBJPHMDABKJV-UHFFFAOYSA-N secoisolariciresinol diglycoside Natural products C1=C(O)C(OC)=CC(CC(COC2C(C(O)C(O)C(CO)O2)O)C(COC2C(C(O)C(O)C(CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-UHFFFAOYSA-N 0.000 claims abstract description 112
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 47
MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims abstract description 15
235000004426 flaxseed Nutrition 0.000 claims abstract description 15
238000011282 treatment Methods 0.000 claims description 13
230000037396 body weight Effects 0.000 claims description 5
239000000287 crude extract Substances 0.000 claims description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 148
235000012000 cholesterol Nutrition 0.000 abstract description 70
238000011161 development Methods 0.000 abstract description 13
201000001320 Atherosclerosis Diseases 0.000 abstract description 11
230000000260 hypercholesteremic effect Effects 0.000 abstract description 8
241001465754 Metazoa Species 0.000 abstract description 7
150000001875 compounds Chemical class 0.000 abstract description 2
241000700159 Rattus Species 0.000 description 47
241000208202 Linaceae Species 0.000 description 38
235000004431 Linum usitatissimum Nutrition 0.000 description 38
210000002966 serum Anatomy 0.000 description 25
241000283973 Oryctolagus cuniculus Species 0.000 description 22
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 21
229940118019 malondialdehyde Drugs 0.000 description 21
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
239000008103 glucose Substances 0.000 description 18
235000006708 antioxidants Nutrition 0.000 description 17
235000005911 diet Nutrition 0.000 description 17
230000037213 diet Effects 0.000 description 17
230000000694 effects Effects 0.000 description 17
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 17
238000011587 new zealand white rabbit Methods 0.000 description 10
206010018473 Glycosuria Diseases 0.000 description 9
230000035780 glucosuria Effects 0.000 description 9
238000000034 method Methods 0.000 description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000013293 zucker diabetic fatty rat Methods 0.000 description 8
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
229960001052 streptozocin Drugs 0.000 description 7
238000012360 testing method Methods 0.000 description 7
230000000747 cardiac effect Effects 0.000 description 6
230000004217 heart function Effects 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
108010023302 HDL Cholesterol Proteins 0.000 description 4
108010028554 LDL Cholesterol Proteins 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
108010069201 VLDL Cholesterol Proteins 0.000 description 4
229930003427 Vitamin E Natural products 0.000 description 4
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
230000003143 atherosclerotic effect Effects 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 4
229960003912 probucol Drugs 0.000 description 4
235000019165 vitamin E Nutrition 0.000 description 4
229940046009 vitamin E Drugs 0.000 description 4
239000011709 vitamin E Substances 0.000 description 4
206010014824 Endotoxic shock Diseases 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
229930182485 cyanogenic glycoside Natural products 0.000 description 3
150000008142 cyanogenic glycosides Chemical class 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930013686 lignan Natural products 0.000 description 3
235000009408 lignans Nutrition 0.000 description 3
150000005692 lignans Chemical class 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
235000020661 alpha-linolenic acid Nutrition 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011461 current therapy Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000036541 health Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
230000003859 lipid peroxidation Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
-1 triglyceride fatty acid Chemical class 0.000 description 2
CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
244000068687 Amelanchier alnifolia Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000013600 Diabetic vascular disease Diseases 0.000 description 1
208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
201000009101 diabetic angiopathy Diseases 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000008635 plant growth Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Landscapes

Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002563381A 1996-04-04 1997-04-03 Utilisation de sdg purifie comme antioxydant Expired - Fee Related CA2563381C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1481896P	1996-04-04	1996-04-04
US60/014,818		1996-04-04
CA002201652A CA2201652C (fr)	1996-04-04	1997-04-03	Utilisation de sdg purifie comme antioxydant

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002201652A Division CA2201652C (fr)	1996-04-04	1997-04-03	Utilisation de sdg purifie comme antioxydant

Publications (2)

Publication Number	Publication Date
CA2563381A1 CA2563381A1 (fr)	1997-10-04
CA2563381C true CA2563381C (fr)	2008-01-22

Family

ID=37451539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002563381A Expired - Fee Related CA2563381C (fr)	1996-04-04	1997-04-03	Utilisation de sdg purifie comme antioxydant

Country Status (1)

Country	Link
CA (1)	CA2563381C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008012106A1 (fr) *	2006-07-28	2008-01-31	Bioriginal Food & Science Corporation	Composition contenant des graisses
CA3008075A1 (fr) *	2015-12-09	2017-06-15	Oy Granula Ab Ltd	Utilisation d'une composition visant a faire baisser le taux de cholesterol chez un mammifere, son procede de preparation, composition et procede de preparation d'un additif alime ntaire contenant ladite composition

1997
- 1997-04-03 CA CA002563381A patent/CA2563381C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2563381A1 (fr)	1997-10-04

Legal Events

Date	Code	Title	Description
2006-10-26	EEER	Examination request
2012-04-03	MKLA	Lapsed

Publication	Publication Date	Title
CA2201652C (fr)	2007-09-11	Utilisation de sdg purifie comme antioxydant
Liu et al.	2022	Phycocyanin: Anti-inflammatory effect and mechanism
US6436406B1 (en)	2002-08-20	Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
CN101977596A (zh)	2011-02-16	大麻素类的新用途
MXPA04003233A (es)	2005-01-25	Metodo y composicion para prevenir o reducir los sintomas del sindrome de resistencia a la insulina.
US20080166420A1 (en)	2008-07-10	Krill Oil Compositions
Baluchnejadmojarad et al.	2003	Garlic extract attenuates time-dependent changes in the reactivity of isolated aorta in streptozotocin-diabetic rats
US20120009278A1 (en)	2012-01-12	Composition To Retard the Onset of Symptoms of Alzheimer's Disease
JPH05194209A (ja)	1993-08-03	血管内皮細胞機能改善剤
KR20010024654A (ko)	2001-03-26	포도 추출물의 인지질 착체화합물의 아테롬성동맥경화치료제로서의 용도
EP1871399B1 (fr)	2011-01-26	Utilisation de la lecithine comme medicament dans le traitement du psoriasis
CA2563952C (fr)	2016-05-17	Utilisations de glycosides pregnanes pour le traitement ou la gestion de l'obesite, de troubles associes a l'obesite et d'autres desordres
AU2002334001B2 (en)	2007-07-19	Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
KR101072175B1 (ko)	2011-10-10	데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물
Siddiqui et al.	2023	Cardioprotective potential of Lavandula stoechas against isoprenaline-induced myocardial necrosis in rats
Hutapea et al.	2021	Hypoglycemic potential of Aloe vera in diabetes mellitus induced by diabetogenic substances and high fat diet: a systematic meta-analysis review
CN115461051B (zh)	2023-11-28	药学组合物及其于治疗帕金森氏症的用途
CN110613712B (zh)	2021-06-29	中药组合物及其在治疗血管炎症和内皮损伤中的应用
US3803319A (en)	1974-04-09	Treating hyperlipemia with isatin
CHEN et al.	1999	Beneficial effects of sanguisorbae radix in renal dysfunction caused by endotoxin in vivo
WO2020104987A1 (fr)	2020-05-28	Composition destinée à être utilisée dans la prévention et/ou le traitement symptomatique du syndrome du côlon irritable
Kuhn et al.	1983	Pharmacology and hypnogenic properties of brotizolam in animals.
CN1148182C (zh)	2004-05-05	茶多酚在制备抑制β-淀粉样蛋白聚集和纤维形成的药物中的应用
Duke et al.	1981	Current views on the treatment of onchocerciasis with diethylcarbamazine citrate and suramin
EP3727359B1 (fr)	2024-04-17	Traitement de la fibrose avec de l'inositol